Search Results - "Ksienski, Doran"

Mandatory seasonal influenza vaccination or masking of British Columbia health care workers: Year 1 by Ksienski, Doran S.

“…OBJECTIVE:The Influenza Prevention Policy (“the Policy”) aims to increase seasonal influenza vaccination coverage among British Columbia (BC) health care…”
Get full text

Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice by Ksienski, Doran, Wai, Elaine S., Croteau, Nicole, Freeman, Ashley T., Chan, Angela, Fiorino, Leathia, Brooks, Edward G., Poonja, Zia, Fenton, David, Geller, Georgia, Irons, Sarah, Lesperance, Mary

“…•Poor ECOG PS patients are excluded from pembrolizumab advanced NSCLC trials.•In this review, median OS was lower if ECOG PS 2 or 3 (versus ≤1) at…”
Get full text

Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors by Ksienski, Doran

“…Just over a decade ago, gastrointestinal tumours were a poorly understood mesenchymal neoplasm unsuccessfully treated with chemotherapy. Cytotoxic therapy for…”
Get full text

Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice by Ksienski, Doran, Truong, Pauline T, Croteau, Nicole S, Chan, Angela, Sonke, Eric, Patterson, Tiffany, Clarkson, Melissa, Lesperance, Mary

“…Background The anti-programmed cell death one antibodies (Anti-PD-1 Ab) pembrolizumab or nivolumab are commonly prescribed to patients with advanced melanoma…”
Get full text

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial by Kowalski, Dariusz M, Cho, Byoung Chul, Lubiniecki, Gregory M, Kush, Debra, Lopes, Gilberto, Adamchuk, Grigory, Ahn, Myung-Ju, Altundag, Ozden, Aoe, Keisuke, Ativitavas, Touch, Beato, Carlos, Bergstrom, Per, Betticher, Daniel, Buddu, Sayeuri, Castro, Hugo, Cay Senler, Filiz, Cerny, Carlos Alexandre Sydow, Chan, Gee-Chen, Chang, Jianhua, Cheng, Susanna, Cherciu, Nelly, Cho, Byoung Chul, Cicenas, Saulius, Cohen, Graham, Costa, Marcos Andre, De Angelis, Flavia, de Azevedo, Sergio Jobim, De Marchi, Pedro Rafael Martins, de The Bustamante Valles, Flor, Doganov, Boyan, Dreosti, Lydia, Duarte, Ricardo, Erman, Mustafa, Fein, Luis, Feng, Jifeng, Fenton, David, Fernandes, Gustavo, Ferreira, Carlos, Fujisaka, Yasuhito, Galvez, Christina, Gil, Nuno, Hall, Jacqueline, Hart, Gregory, He, Yong, Ho, Chung Man James, Horiike, Atsushi, Hu, Yi, Ichiki, Masao, Imamura, Fumio, Jassem, Jacek, Jordaan, Christa, Kaen, Diego, Katakami, Nobuyuki, Kato, Terufumi, Kawaguchi, Tomoya, Kim, Joo Hang, Kowalyszyn, Ruben, Ksienski, Doran, Kubota, Kaoru, Kuusk, Gerli, Laczo, Ibolya, Landers, Gregory, Lazarev, Sergey, Li, Wei, Liu, Zhe, Lopes, Valeria, Lu, Shun, Mas, Luis, Milanova, Zhasmina, Nakahara, Yasuharu, Ohman, Ronny, Ong, Choo Khoon, Ostoros, Gyula, Qin, Shukui, Ramlau, Rodryg, Richardet, Eduardo, Roubec, Jaromir, Rusyn, Andrii, Seki, Nobuhiko, Shimada, Andrea Kazumi, Shparyk, Yaroslav, Sinielnikov, Ivan, Soares, Joao Paulo Holanda, Stara, Zinaida, Tanaka, Hiroshi, Tang, Qiyou, Taranov, Pavel, Tejada, Hermes, Torii, Yoshitaro, Trukhyn, Dmytro, Turdean, Maria, Vera, Luis, Vynnychenko, Ihor, Wang, Jie, Wang, Kai, Yumuk, Fulden, Zambrano, Angela, Zemaitis, Marius, Zhao, Jun, Zhou, Jianying

“…First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a…”
Get full text

Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non–Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis by Ksienski, Doran, Wai, Elaine S., Croteau, Nicole, Fiorino, Leathia, Brooks, Edward, Poonja, Zia, Fenton, Dave, Geller, Georiga, Glick, Daniel, Lesperance, Mary

“…The programmed death 1 antibodies (PD-1 Ab) nivolumab and pembrolizumab improve overall survival (OS) in advanced non–small-cell lung cancer (NSCLC). We…”
Get full text

Safety and clinical efficacy of programmed cell death 1 antibodies (PD-1 Ab) in patients with advanced non-small cell lung cancer (NSCLC) by Ksienski, Doran, Wai, Elaine, Croteau, Nicole, Lesperance, Mary

“…Abstract only 260 Background: In advanced NSCLC, clinical trials have shown significant benefits to pembrolizumab (P) and nivolumab (N). At BC Cancer,…”
Get full text

Experience of nivolumab and pembrolizumab in metastatic non-small cell lung cancer in routine clinical practice (mNSCLC.) by Ksienski, Doran, Brooks, Edward Geoffrey, Fenton, Dave, Fiorino, Leathia, Geller, Georgia Samantha, Poonja, Zia, Glick, Daniel

“…Abstract only…”
Get full text

Durvalumab Following Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Differences in Survival Based on Age and Post-Progression Systemic Therapy by Ksienski, Doran, Truong, Pauline T., Bone, Jeffrey N., Egli, Sarah, Clarkson, Melissa, Patterson, Tiffany, Lesperance, Mary, Lakkunarajah, Suganija

“…Concurrent chemoradiotherapy (cCRT) followed by 1 year of the immune checkpoint inhibitor (ICI) durvalumab is standard of care for patients with unresectable…”
Get full text

Safety and efficacy of pembrolizumab for advanced nonsmall cell lung cancer: before and during the COVID-19 pandemic by Ksienski, Doran, Gupta, Sapna, Truong, Pauline T., Bone, Jeffrey, Chan, Angela, Alex, Deepu, Hart, Jason, Pollock, Philip, Patterson, Tiffany, Clarkson, Melissa, Dissanayake, Dushanthi, Sonke, Eric, Lesperance, Mary

“…Purpose The COVID-19 pandemic changed diagnostic and treatment pathways in oncology. We compared the safety and efficacy of pembrolizumab amongst advanced…”
Get full text

Patterns of Referral and Resection Among Patients with Liver-Only Metastatic Colorectal Cancer (MCRC) by Ksienski, Doran, Woods, Ryan, Speers, Caroline, Kennecke, Hagen

“…Background Rates of metastatectomy vary among patients with liver-only metastatic colorectal cancer (MCRC). This study describe predictors of referral to a…”
Get full text

Advanced cutaneous squamous cell carcinoma: Impact of age on the safety and efficacy of cemiplimab and the prognostic significance of blood biomarkers by Ksienski, Doran, Truong, Pauline T., Bone, Jeffrey N., Egli, Sarah, Clarkson, Melissa, Patterson, Tiffany, Lesperance, Mary, Lakkunarajah, Suganija

“…Age-related differences in the safety profile of cemiplimab for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) have not…”
Get full text

Pembrolizumab (Pem) for advanced non-small cell lung cancer (aNSCLC): Efficacy and safety in everyday clinical practice by Ksienski, Doran, Wai, Elaine S., Croteau, Nicole, Freeman, Ashley, Fiorino, Leathia, Chan, Angela, Geller, Georgia Samantha, Poonja, Zia, Brooks, Edward Geoffrey, Fenton, Dave, Irons, Sarah, Lesperance, Mary

“…Abstract only e20506 Background: In clinical trials, Pem improves overall survival (OS) compared to chemotherapy in a subset of patients (pts) with aNSCLC…”
Get full text

Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab by Ksienski, Doran, Wai, Elaine S., Alex, Deepu, Croteau, Nicole S., Freeman, Ashley T., Chan, Angela, Patterson, Tiffany, Clarkson, Melissa, Fiorino, Leathia, Poonja, Zia, Fenton, David, Irons, Sarah, Lesperance, Mary

Get full text

Immune related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab by Ksienski, Doran, Truong, Pauline T., Croteau, Nicole S., Chan, Angela, Sonke, Eric, Patterson, Tiffany, Clarkson, Melissa, Hackett, Samuel, Lesperance, Mary

“…Programmed cell-death 1 antibodies (PD-1 Ab) improve overall survival (OS) for patients with advanced melanoma in trials; however, safety data in patients…”
Get full text

Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab by Ksienski, Doran, Wai, Elaine S., Croteau, Nicole S., Freeman, Ashley T., Chan, Angela, Fiorino, Leathia, Poonja, Zia, Fenton, David, Patterson, Tiffany, Irons, Sarah, Lesperance, Mary

“…To explore the association of age with development of immune related adverse events (irAE) and survival in patients with advanced nonsmall cell lung cancer…”
Get full text

First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic by Lakkunarajah, Suganija, Truong, Pauline T., Bone, Jeffrey N., Hughesman, Curtis, Yip, Stephen, Alex, Deepu, Hart, Jason, Pollock, Philip, Egli, Sarah, Clarkson, Melissa, Lesperance, Mary, Ksienski, Doran

Get full text

Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors by Doran Ksienski

“…Just over a decade ago, gastrointestinal tumours were a poorly understood mesenchymal neoplasm unsuccessfully treated with chemotherapy. Cytotoxic therapy for…”
Get full text

Metastatic Uterine Leiomyosarcoma and Eosinophilia by Ksienski, Doran, Cheung, Winson Y.

“…Uterine sarcomas account for approximately 3% to 7% of all uterine malignancies. Distinguishing benign and malignant myomas based on physical examination and…”
Get full text

Chest pain and cough in a 33-year-old postpartum woman by Ksienski, Doran, Malhotra, Samir, Walker, Blair, Levy, Robert D

Get more information